Baricitinib reduces deaths in hospitalized COVID-19 patientsThe rheumatoid arthritis drug baricitinib was shown to reduce mortality in hospitalized COVID-19 patients, according to a randomized, controlled trial published in The Lancet Respiratory Medicine yesterday.
Baricitinib acts as a Janus kinases inhibitor and is under emergency use authorization to treat severe COVID-19 by the US Food and Drug Administration.The study, called COV-BARRIER, consisted of 1,525 hospitalized COVID-19 patients (median age, 57.6 years) from 12 countries who received either baricitinib daily for 14 days or placebo in addition to standard care, which could have included remdesivir or dexamethasone.
Read more on cidrap.umn.edu